Stocks and Investing Stocks and Investing
Tue, March 5, 2024

John Sourbeer Maintained (AKYA) at Strong Buy with Increased Target to $7.5 on, Mar 5th, 2024


Published on 2024-10-28 09:27:10 - WOPRAI, John Sourbeer
  Print publication without navigation


John Sourbeer of UBS, Maintained "Akoya Biosciences, Inc." (AKYA) at Strong Buy with Increased Target from $7 to $7.5 on, Mar 5th, 2024.

John has made no other calls on AKYA in the last 4 months.



There are 3 other peers that have a rating on AKYA. Out of the 3 peers that are also analyzing AKYA, 1 agrees with John's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Subbu Nambi of "Guggenheim" Initiated at Hold on, Thursday, December 14th, 2023


These are the ratings of the 2 analyists that currently disagree with John


  • David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $8 on, Monday, November 13th, 2023
  • Mason Carrico of "Stephens & Co." Maintained at Buy with Decreased Target to $9 on, Monday, November 13th, 2023
Contributing Sources